HUNDREDS of workers at GSK in Ulverston have been told who will lose their jobs within the next two years.

In October GSK announced it was cutting 200 of the 360 jobs at its Ulverston site and last week bosses informed staff which positions would be lost.

The redundancies follow GSK's decision to stop manufacturing ingredients of sterile injections at Ulverston.

The news has been a devastating blow for Ulverston which had previously been poised to benefit from a £350m biopharmaceutical facility.

In July 2017 GSK announced the investment would no longer go ahead, a U-turn which had been exclusively revealed by The Mail in December 2016.

A GSK spokesperson said: “Last week, all GSK Ulverston employees were informed of their future employment status. Those employees who will leave the organisation over the next two years will receive a package of support and re-training.

"GSK will continue to support the community through measures to foster economic regeneration and job creation.

"Availability of the products currently made at Ulverston will be unaffected by the changes we are setting out today.

"Neither the review nor the steps we have set out are related to the UK’s decision to leave the European Union.

"GSK employs 17,000 people in the UK and has a substantial manufacturing presence. Since 2012 we have invested approximately £1.5 billion in our UK manufacturing sites.”

Furness independent MP John Woodcock established the GSK Ulverston Taskforce after the job cuts were first announced.

He said: “This is a very tough period for many highly skilled personnel who have given great commitment to GSK.

“From the trade unions and local management to the local council, every member of our taskforce is working together to push the company for the best support package possible for those affected.

“In particular, I hope that the retraining fund pledged by GSK will be generous and effective in helping employees find alternative work.”